Imatinib Completed Phase 2 Trials for Recurrent Uterine Sarcoma / Uterine Carcinosarcoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00075400Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer